NCT ID NCT06014502

Title Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

 Phase
 Phase 1

 Date Added
 2023-08-28

**Location** Louisiana, United States

Texas, United States

Prior IO Allowed No CRC-directed No

Status Recruiting

Drugs IMGS-001

Tags MSI-H/ MMRd

NCT ID NCT06013111

Title An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+

Locally Advanced and/or Metastatic Solid Tumors

PhasePhase 1Date Added2023-08-28LocationChinaPrior IO AllowedYesCRC-directedYes

Status Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

Recruiting

NCT ID NCT06010901

Title A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib

Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

PhasePhase 1Date Added2023-08-25LocationChinaPrior IO AllowedYesCRC-directedYes

**Status** Recruiting

**Drugs** Anlotinib hydrochloride capsules, Penpulimab Injection, TQB2618 injection

Tags MSI-H/ MMRd, MSS/ MMRp

**NCT ID** NCT06011772

Title A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF

Wild-Type Metastatic Colorectal Cancer

Phase Early Phase 1

Date Added 2023-08-25

**Location** New York, United States

Prior IO Allowed Yes
CRC-directed Yes

Status Suspended

**Drugs** fluorouracil, Irinotecan, Leucovorin, oxaliplatin

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06008119

Title Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Phase 3

**Date Added** 2023-08-23

 Location
 China

 Prior IO Allowed
 Yes

 CRC-directed
 Yes

**Status** Recruiting

Drugs Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT06006923

Title Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

 Phase
 Phase 2

 Date Added
 2023-08-23

**Location** California, United States

Florida, United States Illinois, United States Pennsylvania, United States Washington, United States

Prior IO Allowed No
CRC-directed Yes
Status Recruiting

**Drugs** Pembrolizumab, Regorafenib, Keytruda, Stivarga

Tags MSI-H/ MMRd

NCT ID NCT05999812

Title Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

 Phase
 Phase 2

 Date Added
 2023-08-21

**Location** Texas, United States

Prior IO Allowed No
CRC-directed Yes
Status Recruiting

Drugs all trans Retinoic Acid, Atezolizumab, Bevacizumab

Tags MSS/ MMRp

NCT ID NCT05990543

Title Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

 Phase
 Phase 1

 Date Added
 2023-08-14

Location

Prior IO Allowed Yes
CRC-directed Yes

Status Not yet recruiting

Drugs Nelmastobart and Capecitabine

Tags MSI-H/ MMRd, MSS/ MMRp

NCT ID NCT05976906

Title Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors

Phase Phase 1

Date Added 2023-08-04

Location China

Prior IO Allowed Yes

CRC-directed Yes

**Status** Recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp

**NCT ID** NCT05973487

Title A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or

Metastatic Solid Tumors

 Phase
 Phase 1

 Date Added
 2023-08-03

**Location** Arizona, United States

California, United States
Connecticut, United States
Florida, United States
Illinois, United States
Kentucky, United States
Michigan, United States
Minnesota, United States
New York, United States
North Carolina, United States

Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States

Prior IO Allowed Yes

CRC-directed Yes

Status Recruiting

Drugs

Tags MSI-H/ MMRd, MSS/ MMRp